Press Release: European Medicines Agency recommends authorisation of additional vaccine for influenza pandemic (AH1N1) 2009

The European Medicines Agency (EMEA), on 2 October 2009, recommended to the European Commission that an additional vaccine against influenza A(H1N1) (‘swine flu’), Celvapan from Baxter, be granted a marketing authorisation. This recommendation follows the authorisation of Focetria, from Novartis, and Pandemrix, from GlaxoSmithKline, by the European Commission on 29 September 2009.